Xeltis says the device is designed to reduce infection and reintervention rates compared to existing arteriovenous rafts ... patency at 12 months. The graft patency was defined as any flow through ...
Designed to reduce the risk of graft-related infection from MRSA, P.aeruginosa, and S.epidermidis, INTERGARD SILVER is the first antimicrobial graft on the market. The safety and benefits of ...
Background and aim: EBV infection and post-transplant lymphoproliferative disease (PTLD) are closely linked, but the contribution of EBV to graft dysfunction (GD) has not been clearly reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback